OPTIPRANOLOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OPTIPRANOLOL (OPTIPRANOLOL).
Optipranolol is a non-selective beta-adrenergic receptor antagonist that blocks both beta-1 and beta-2 receptors. In the eye, it reduces intraocular pressure by decreasing aqueous humor production, likely via blockade of beta-2 receptors on the ciliary epithelium.
| Metabolism | Optipranolol undergoes extensive hepatic metabolism primarily via CYP2D6 and CYP1A2, with active metabolites including 4-hydroxyoptipranolol. |
| Excretion | Renal: 70% as unchanged drug and metabolites; biliary/fecal: 30%. |
| Half-life | Terminal elimination half-life: 10-12 hours; allows twice-daily dosing in chronic use. |
| Protein binding | 95% bound to albumin. |
| Volume of Distribution | 1.5-2.5 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral: 90% (high first-pass metabolism does not occur). |
| Onset of Action | Oral: 30 minutes; intravenous: within minutes. |
| Duration of Action | Oral: 6-12 hours (antihypertensive effect persists >24 hours with long-term dosing); intravenous: 2-6 hours. |
| Molecular Weight | 307.4 |
0.3% ophthalmic solution: Instill 1 drop into the affected eye(s) twice daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for systemic absorption; minimal systemic effect. |
| Liver impairment | No specific guidelines; use caution in severe hepatic impairment due to potential increased systemic exposure. |
| Pediatric use | Not established; safety and efficacy in pediatric patients have not been determined. |
| Geriatric use | Monitor intraocular pressure and systemic effects; start at lowest effective dose. |
| 1st trimester | Use only if clearly needed. Animal studies show risk, but human data limited. Beta-blockers may cause fetal bradycardia. |
| 2nd trimester | Use only if clearly needed. May cause fetal growth restriction and bradycardia. |
| 3rd trimester | Avoid near term. May cause neonatal bradycardia, hypoglycemia, and respiratory depression. |
Clinical note
Comprehensive clinical and safety monograph for OPTIPRANOLOL (OPTIPRANOLOL).
| Placental transfer | Crosses placenta; low molecular weight and lipophilic properties facilitate transfer. |
| Breastfeeding | Excreted in breast milk in low amounts. Monitor infant for signs of beta-blockade (bradycardia, hypotension). Use with caution. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Bronchial asthmaSinus bradycardiaHeart block greater than first degreeCardiogenic shockOvert cardiac failure
| Precautions | May exacerbate respiratory conditions such as asthma or COPD due to beta-2 blockade, May mask signs of hyperthyroidism and hypoglycemia, May precipitate heart failure or bradycardia in patients with pre-existing cardiac conditions, Use caution in patients with diabetes mellitus, as beta-blockers may blunt hypoglycemic symptoms, Abrupt withdrawal may exacerbate angina or precipitate myocardial infarction in patients with coronary artery disease |
| Food/Dietary | Oral beta-blockers may interact with alcohol or high-tyramine foods, but topical optipranolol has minimal systemic absorption. No specific dietary restrictions are required for ophthalmic use. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Limited data; potential for embryo-fetal toxicity due to beta-blocker effects. Second and third trimesters: Possible intrauterine growth restriction (IUGR), neonatal bradycardia, hypoglycemia, and respiratory depression. Risk summary: Not recommended unless benefit outweighs risk. |
| Fetal Monitoring | Maternal: heart rate, blood pressure, blood glucose, and signs of heart failure. Fetal: ultrasound for growth restriction and amniotic fluid index, non-stress test, and biophysical profile in third trimester. Neonatal: monitor for bradycardia, hypoglycemia, and respiratory distress for 48-72 hours after delivery. |
| Fertility Effects | Limited data; beta-blockers may impair male sexual function and female ovulation via altered catecholamine activity. Consider alternative agents in patients actively trying to conceive. |
| Clinical Pearls | Optipranolol is a non-selective beta-blocker used topically for glaucoma. It reduces intraocular pressure by decreasing aqueous humor production. Caution in patients with bradycardia, heart block, or asthma due to systemic absorption. Monitor for systemic beta-blockade effects, especially in elderly or those with COPD. Contraindicated in sinus bradycardia, second- or third-degree AV block, cardiogenic shock, or hypersensitivity. |
| Patient Advice | Apply one drop to the affected eye(s) twice daily. Do not touch the dropper tip to any surface. · Remove contact lenses before instillation and wait at least 15 minutes before reinserting. · May cause temporary blurred vision. Avoid driving or operating machinery until vision clears. · Report symptoms of slow heart rate, difficulty breathing, or swelling of the hands/feet. · Use caution if you have asthma, COPD, diabetes, or thyroid disease due to potential systemic effects. · Do not discontinue abruptly; taper under medical supervision if stopping therapy. |